Precision BioSciences Announces Plans for First-In-Human Clinical Trials of PBGENE-DMD Gene Editing Therapy for Duchenne Muscular Dystrophy in 2025

Reuters

07-16

Precision BioSciences Announces Plans for First-In-Human Clinical Trials of PBGENE-DMD Gene Editing Therapy for Duchenne Muscular Dystrophy in 2025

Precision BioSciences, Inc. has announced plans to advance its PBGENE-DMD program, an innovative in vivo gene editing approach for treating Duchenne muscular dystrophy (DMD), towards clinical trials. The company is targeting the submission of an Investigational New Drug $(IND.AU)$ and/or Clinical Trial Application $(CTA.UK)$ by 2025, with initial clinical data expected in 2026. This approach aims to address mutations in the 'hot spot' region between exons 45-55, potentially benefiting up to 60% of DMD patients. Recent preclinical data indicate a significant increase in dystrophin-positive muscle cells, which may translate into improved muscle function. Precision BioSciences plans to present the complete dataset at a future scientific conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250716326036) on July 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551147783"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551147783\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2551147783?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551147783","market":"nz","top_or_hot":-1,"title":"Precision BioSciences Announces Plans for First-In-Human Clinical Trials of PBGENE-DMD Gene Editing Therapy for Duchenne Muscular Dystrophy in 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Precision BioSciences Announces Plans for First-In-Human Clinical Trials of PBGENE-DMD Gene Editing Therapy for Duchenne Muscular Dystrophy in 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Precision BioSciences, Inc. has announced plans to advance its PBGENE-DMD program, an innovative in vivo gene editing approach for treating Duchenne muscular dystrophy (DMD), towards clinical trials. The company is targeting the submission of an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> and/or Clinical Trial Application <a href=\"https://laohu8.com/S/CTA.UK\">$(CTA.UK)$</a> by 2025, with initial clinical data expected in 2026. This approach aims to address mutations in the 'hot spot' region between exons 45-55, potentially benefiting up to 60% of DMD patients. Recent preclinical data indicate a significant increase in dystrophin-positive muscle cells, which may translate into improved muscle function. Precision BioSciences plans to present the complete dataset at a future scientific conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250716326036) on July 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precision BioSciences Announces Plans for First-In-Human Clinical Trials of PBGENE-DMD Gene Editing Therapy for Duchenne Muscular Dystrophy in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecision BioSciences Announces Plans for First-In-Human Clinical Trials of PBGENE-DMD Gene Editing Therapy for Duchenne Muscular Dystrophy in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-16 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Precision BioSciences Announces Plans for First-In-Human Clinical Trials of PBGENE-DMD Gene Editing Therapy for Duchenne Muscular Dystrophy in 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Precision BioSciences, Inc. has announced plans to advance its PBGENE-DMD program, an innovative in vivo gene editing approach for treating Duchenne muscular dystrophy (DMD), towards clinical trials. The company is targeting the submission of an Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> and/or Clinical Trial Application <a href=\"https://laohu8.com/S/CTA.UK\">$(CTA.UK)$</a> by 2025, with initial clinical data expected in 2026. This approach aims to address mutations in the 'hot spot' region between exons 45-55, potentially benefiting up to 60% of DMD patients. Recent preclinical data indicate a significant increase in dystrophin-positive muscle cells, which may translate into improved muscle function. Precision BioSciences plans to present the complete dataset at a future scientific conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250716326036) on July 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL2CQR0f:1","article_id":"2551147783","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551147783","pubTimestamp":1752663691,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Precision BioSciences Announces Plans for First-In-Human Clinical Trials of PBGENE-DMD Gene Editing Therapy for Duchenne Muscular Dystrophy in 2025. Precision BioSciences, Inc. has announced plans to advance its PBGENE-DMD program, an innovative in vivo gene editing approach for treating Duchenne muscular dystrophy , towards clinical trials. The company is targeting the submission of an Investigational New Drug  and/or Clinical Trial Application  by 2025, with initial clinical data expected in 2026. This approach aims to address mutations in the 'hot spot' region between exons 45-55, potentially benefiting up to 60% of DMD patients. Recent preclinical data indicate a significant increase in dystrophin-positive muscle cells, which may translate into improved muscle function. Precision BioSciences plans to present the complete dataset at a future scientific conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT stri","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DTIL":"Precision Biosciences Inc"},"translate_title":"Precision BioSciences宣布计划于2025年开展PBGENE-DMD基因编辑疗法治疗杜氏肌营养不良症的首次人体临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DTIL":0.9},"content_text":"Precision BioSciences Announces Plans for First-In-Human Clinical Trials of PBGENE-DMD Gene Editing Therapy for Duchenne Muscular Dystrophy in 2025\n    \n\n        Precision BioSciences, Inc. has announced plans to advance its PBGENE-DMD program, an innovative in vivo gene editing approach for treating Duchenne muscular dystrophy (DMD), towards clinical trials. The company is targeting the submission of an Investigational New Drug $(IND.AU)$ and/or Clinical Trial Application $(CTA.UK)$ by 2025, with initial clinical data expected in 2026. This approach aims to address mutations in the 'hot spot' region between exons 45-55, potentially benefiting up to 60% of DMD patients. Recent preclinical data indicate a significant increase in dystrophin-positive muscle cells, which may translate into improved muscle function. Precision BioSciences plans to present the complete dataset at a future scientific conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250716326036) on July 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}